The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines

Kenrad Edwin Nelson, M. L. Clements, P. Miotti, S. Cohn, B. F. Polk

Research output: Contribution to journalArticle

Abstract

Study Objective: To ascertain whether subjects infected with human immunodeficiency virus (HIV) generally develop protective hemagglutination inhibition antibody responses to inactivated influenza vaccines. Design: Prospective study of 104 persons before and after immunization. Setting: Outpatient clinic and hospital ward. Patients: Persons with the acquired immunodeficiency syndrome (AIDS) (n = 25), AIDS-related complex (n = 14), and HIV-seropositive men with only lymphadenopathy or no symptoms (n = 27). Controls were HIV-seronegative homosexual men (n = 22) and HIV-seronegative heterosexuals (n = 16). Interventions: Subjects were immunized with inactivated vaccines containing 15 μg of ech of the following influenza virus hemagglutinins: A/Taiwan/1/86 (HINI), A/Mississippi/1/85 (H3N2), A/Chile/1/83 (HINI), and B/Ann Arbor/1/86. Measurements and Main Results: Fourfold or greater antibody responses occurred less frequently in subjects with HIV infections than in HIV-seronegative controls. Protective levels (1:64 or greater) of hemagglutination inhibition antibodies were attained by 94% to 100% of HIV-seronegative controls, 52% to 89% of HIV-seropositive asymptomatic subjects, and 13% to 50% of subjects with AIDS or AIDS-related complex. No increase in the prevalence or level of serum HIV p24 antigen or clinical deterioration was detected among HIV-infected persons after influenza immunization. Conclusions: Because of the poor antibody responses to influenza vaccines among HIV-infected subjects, even in many with no or minimal symptoms, alternative strategies for preventing influenza, such as booster doses of influenza vaccine, prophylaxis with amantidine, or both should be considered.

Original languageEnglish (US)
Pages (from-to)383-388
Number of pages6
JournalAnnals of Internal Medicine
Volume109
Issue number5
StatePublished - 1988

Fingerprint

Influenza Vaccines
Virus Diseases
Antibody Formation
HIV
Acquired Immunodeficiency Syndrome
Inactivated Vaccines
Hemagglutination
Human Influenza
Immunization
Hospital Outpatient Clinics
Mississippi
Chile
Heterosexuality
Influenza A virus
Hemagglutinins
Taiwan
Prospective Studies
Antigens

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines. / Nelson, Kenrad Edwin; Clements, M. L.; Miotti, P.; Cohn, S.; Polk, B. F.

In: Annals of Internal Medicine, Vol. 109, No. 5, 1988, p. 383-388.

Research output: Contribution to journalArticle

Nelson, Kenrad Edwin ; Clements, M. L. ; Miotti, P. ; Cohn, S. ; Polk, B. F. / The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines. In: Annals of Internal Medicine. 1988 ; Vol. 109, No. 5. pp. 383-388.
@article{8782aaf80fa94e00bd539eecbc157816,
title = "The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines",
abstract = "Study Objective: To ascertain whether subjects infected with human immunodeficiency virus (HIV) generally develop protective hemagglutination inhibition antibody responses to inactivated influenza vaccines. Design: Prospective study of 104 persons before and after immunization. Setting: Outpatient clinic and hospital ward. Patients: Persons with the acquired immunodeficiency syndrome (AIDS) (n = 25), AIDS-related complex (n = 14), and HIV-seropositive men with only lymphadenopathy or no symptoms (n = 27). Controls were HIV-seronegative homosexual men (n = 22) and HIV-seronegative heterosexuals (n = 16). Interventions: Subjects were immunized with inactivated vaccines containing 15 μg of ech of the following influenza virus hemagglutinins: A/Taiwan/1/86 (HINI), A/Mississippi/1/85 (H3N2), A/Chile/1/83 (HINI), and B/Ann Arbor/1/86. Measurements and Main Results: Fourfold or greater antibody responses occurred less frequently in subjects with HIV infections than in HIV-seronegative controls. Protective levels (1:64 or greater) of hemagglutination inhibition antibodies were attained by 94{\%} to 100{\%} of HIV-seronegative controls, 52{\%} to 89{\%} of HIV-seropositive asymptomatic subjects, and 13{\%} to 50{\%} of subjects with AIDS or AIDS-related complex. No increase in the prevalence or level of serum HIV p24 antigen or clinical deterioration was detected among HIV-infected persons after influenza immunization. Conclusions: Because of the poor antibody responses to influenza vaccines among HIV-infected subjects, even in many with no or minimal symptoms, alternative strategies for preventing influenza, such as booster doses of influenza vaccine, prophylaxis with amantidine, or both should be considered.",
author = "Nelson, {Kenrad Edwin} and Clements, {M. L.} and P. Miotti and S. Cohn and Polk, {B. F.}",
year = "1988",
language = "English (US)",
volume = "109",
pages = "383--388",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "5",

}

TY - JOUR

T1 - The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines

AU - Nelson, Kenrad Edwin

AU - Clements, M. L.

AU - Miotti, P.

AU - Cohn, S.

AU - Polk, B. F.

PY - 1988

Y1 - 1988

N2 - Study Objective: To ascertain whether subjects infected with human immunodeficiency virus (HIV) generally develop protective hemagglutination inhibition antibody responses to inactivated influenza vaccines. Design: Prospective study of 104 persons before and after immunization. Setting: Outpatient clinic and hospital ward. Patients: Persons with the acquired immunodeficiency syndrome (AIDS) (n = 25), AIDS-related complex (n = 14), and HIV-seropositive men with only lymphadenopathy or no symptoms (n = 27). Controls were HIV-seronegative homosexual men (n = 22) and HIV-seronegative heterosexuals (n = 16). Interventions: Subjects were immunized with inactivated vaccines containing 15 μg of ech of the following influenza virus hemagglutinins: A/Taiwan/1/86 (HINI), A/Mississippi/1/85 (H3N2), A/Chile/1/83 (HINI), and B/Ann Arbor/1/86. Measurements and Main Results: Fourfold or greater antibody responses occurred less frequently in subjects with HIV infections than in HIV-seronegative controls. Protective levels (1:64 or greater) of hemagglutination inhibition antibodies were attained by 94% to 100% of HIV-seronegative controls, 52% to 89% of HIV-seropositive asymptomatic subjects, and 13% to 50% of subjects with AIDS or AIDS-related complex. No increase in the prevalence or level of serum HIV p24 antigen or clinical deterioration was detected among HIV-infected persons after influenza immunization. Conclusions: Because of the poor antibody responses to influenza vaccines among HIV-infected subjects, even in many with no or minimal symptoms, alternative strategies for preventing influenza, such as booster doses of influenza vaccine, prophylaxis with amantidine, or both should be considered.

AB - Study Objective: To ascertain whether subjects infected with human immunodeficiency virus (HIV) generally develop protective hemagglutination inhibition antibody responses to inactivated influenza vaccines. Design: Prospective study of 104 persons before and after immunization. Setting: Outpatient clinic and hospital ward. Patients: Persons with the acquired immunodeficiency syndrome (AIDS) (n = 25), AIDS-related complex (n = 14), and HIV-seropositive men with only lymphadenopathy or no symptoms (n = 27). Controls were HIV-seronegative homosexual men (n = 22) and HIV-seronegative heterosexuals (n = 16). Interventions: Subjects were immunized with inactivated vaccines containing 15 μg of ech of the following influenza virus hemagglutinins: A/Taiwan/1/86 (HINI), A/Mississippi/1/85 (H3N2), A/Chile/1/83 (HINI), and B/Ann Arbor/1/86. Measurements and Main Results: Fourfold or greater antibody responses occurred less frequently in subjects with HIV infections than in HIV-seronegative controls. Protective levels (1:64 or greater) of hemagglutination inhibition antibodies were attained by 94% to 100% of HIV-seronegative controls, 52% to 89% of HIV-seropositive asymptomatic subjects, and 13% to 50% of subjects with AIDS or AIDS-related complex. No increase in the prevalence or level of serum HIV p24 antigen or clinical deterioration was detected among HIV-infected persons after influenza immunization. Conclusions: Because of the poor antibody responses to influenza vaccines among HIV-infected subjects, even in many with no or minimal symptoms, alternative strategies for preventing influenza, such as booster doses of influenza vaccine, prophylaxis with amantidine, or both should be considered.

UR - http://www.scopus.com/inward/record.url?scp=0023714258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023714258&partnerID=8YFLogxK

M3 - Article

C2 - 2970238

AN - SCOPUS:0023714258

VL - 109

SP - 383

EP - 388

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 5

ER -